AstraZeneca announced that the European Medicines Agency has accepted the Marketing Authorisation Variation for Forxiga (dapagliflozin) for use as an oral adjunct treatment to insulin in adults with type-1 diabetes (T1D).
Viela Bio announced that it has incorporated as an independent inflammation- and autoimmunity-focused biotechnology company after spinning out from MedImmune, the global biologics research and development arm of AstraZeneca.
Pelago Bioscience AB has entered into a new strategic research collaboration and license agreement with AstraZeneca. In the last two years, the companies have collaborated on numerous Cellular Thermal...
Ionis Pharmaceuticals, Inc. announced that it has licensed AZD2373 to the global, science-led biopharmaceutical company AstraZeneca. AstraZeneca will be responsible for developing and commercializing the drug.
AstraZeneca, an international biopharmaceutical company, and the Internet Initiatives Development Fund (IIDF) signed a Memorandum of Intent to collaborate in the area of digital solutions for the pharmaceutical industry
Companies’ financial success is often down to the strategic deals they are able to make with other pharmaceutical companies to enable them to develop the next leading drug in the market, observes GlobalData
The research project DRIVE-AB has determined that a market entry reward of $1 billion per antibiotic globally could significantly increase the number of new antibiotics coming to the market in the next 30 years